• Brian Godman, Anna Bucsics, Thomas Burkhardt, Alan Haycox, Hans Seyfried, and Peter Wieninger.
• Institute for Pharmacological Research 'Mario Negri', Milan, Italy, and Prescribing Research Group, University of Liverpool Management School, Chatham Street, Liverpool L69 7ZH, UK; Via La Masa 19, Milan, Italy. godman@marionegri.it.
• Expert Rev Pharmacoecon Outcomes Res. 2008 Aug 1; 8 (4): 357-71.

AbstractPharmaceutical expenditure continued to rise steadily in Austria during the 1990s and early 2000s despite a variety of reforms. However, recent reforms and initiatives have moderated the growth rate. These initiatives include transparent pricing of new drugs and generics, greater restrictions on the prescribing of new drugs and voluntary price reductions. Alongside this, there have also been initiatives to enhance rational and efficient prescribing. The lack of published data makes it difficult to fully analyze the impact of individual reforms. In addition, some reforms have only recently been introduced. Despite this, implications can be drawn for key stakeholder groups in the future. This includes pharmaceutical companies continuing to need to demonstrate substantially added benefit for their new drug to command average European prices. Otherwise, premiums will be restricted to a maximum 10% above the price of current standards. In addition, companies will need to continue to lower the price of their brands in interchangeable classes as standards become available as generics. The alternative will be prescribing restrictions. Further reforms will be needed in Austria to meet government growth targets for pharmaceutical expenditure of only 3-4% per annum, while continuing to fund new innovative drugs and increased volumes with greater prevalence of chronic diseases. Possible future measures and their implications for key stakeholder groups will also be discussed.

6 keywords...

hide…